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ABSTRACT
Numerous human genetic diseases are caused
by mutations that give rise to aberrant alterna-
tive splicing. Recently, several of these debilitating
disorders have been shown to be amenable for
splice-correcting oligonucleotides (SCOs) that
modify splicing patterns and restore the pheno-
type in experimental models. However, transla-
tional approaches are required to transform SCOs
into usable drug products. In this study, we present
a new cell-penetrating peptide, PepFect14 (PF14),
which efficiently delivers SCOs to different cell
models including HeLa pLuc705 and mdx mouse
myotubes; a cell culture model of Duchenne’s
muscular dystrophy (DMD). Non-covalent PF14-
SCO nanocomplexes induce splice-correction at
rates higher than the commercially available
lipid-based vector Lipofectamine
TM 2000 (LF2000)
and remain active in the presence of serum.
Furthermore, we demonstrate the feasibility of in-
corporating this delivery system into solid formula-
tions that could be suitable for several therapeutic
applications. Solid dispersion technique is utilized
and the formed solid formulations are as active
as the freshly prepared nanocomplexes in solution
even when stored at an elevated temperatures for
several weeks. In contrast, LF2000 drastically loses
activity after being subjected to same procedure.
This shows that using PF14 is a very promising
translational approach for the delivery of SCOs in
different pharmaceutical forms.
INTRODUCTION
Despite the tremendous success of basic biomedical
research in the last decades, new-drug output from
pharmaceutical companies has been constant over the
last 60 years and mostly based on small molecules (1).
This gap between discoveries and therapeutics has
recently led to intense interest in translational research;
to transform biomedical discoveries into commercializable
drug products (2). One group of gene modulating agents
showing great potential as therapeutic drug products is
splice-correcting oligonucleotides (SCOs). Recent studies
using high-throughput sequencing indicate that 95–100%
of human pre-mRNAs have alternative splice forms (3).
Mutations that affect alternative pre-mRNA splicing have
been linked to a variety of cancers and genetic diseases,
and SCOs can be used to silence mutations that cause
aberrant splicing, thus restoring correct splicing and
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Duchenne’s muscular dystrophy (DMD), a genetic
disease that affects 1 in 3500 young boys worldwide (6).
DMD is a neuromuscular disorder caused mainly by
nonsense or frame-shift mutations in the dystrophin
gene. SCOs are used to induce targeted ‘exon skipping’
and to correct the reading frame of mutated dystrophin
mRNA such that shorter, partially-functional dystrophin
forms are produced (7). SCOs targeting exon 51 are cur-
rently in human clinical trials in various parts of Europe
to treat DMD (8,9). However, translating the promising
results of SCOs into bed-side drug products requires op-
timization of many parameters ranging from enhancement
of cellular uptake and biodistribution to pharmaceutical
formulation and long-term stability.
SCOs are antisense oligonucleotides (ONs) ranging
from 15 to 25 bases in length. In contrast to the normal
antisense approach, SCOs must not activate RNase H,
which would destroy the pre-mRNA target before it
could be spliced (4,5). That is why these ONs are of dif-
ferent chemical nature than DNA and RNA. 20-O-methyl
RNA (20-OMe) and phosphorothioate (PS) RNA are
among the chemistries successfully utilized to induce
splice-correction (4). Such chemical modiﬁcations impart
better annealing with RNA and enhance the serum stabil-
ity of the ONs (10). For these reasons PS-20-OMe SCOs
are used in this study. From a pharmaceutical perspective,
PS-20-OMe SCOs are to be considered class III drugs in
the biopharmaceutical classiﬁcation system (11), with high
solubility and low permeability owing to their high mo-
lecular weight and dense charge distribution (12). That is
why several methods have been devised to enhance their
uptake into cells. Cationic liposomes have been routinely
used as delivery vectors for ONs; however, toxicity
remains a signiﬁcant problem, according to several
in vivo ﬁndings (13).
One class of vectors that appears potent for this purpose
without the associated toxicity of cationic liposomes is
cell-penetrating peptides (CPPs). CPPs are polybasic
and/or amphipathic peptides, usually less than 30 amino
acids in length, that possess the ability to translocate
across cellular plasma membranes. They have gained
much attention in recent years due to their ability to efﬁ-
ciently and safely deliver an array of therapeutic cargos,
from small molecules to nanopaticles both in vitro and
in vivo (14,15). For splice-correction, CPPs covalently
conjugated to different SCOs have been reported to suc-
cessfully induce splice-correction in different models
(7,16). However, despite being less toxic, the transfection
efﬁciencies reported have generally been less than those
achieved utilizing lipid-based vectors such as (LF2000)
(17). Interestingly, some CPPs have been successfully
exploited for ON delivery using a non-covalently complex-
ation strategy (18). Having net positive charge, such CPPs
have been shown to form nano-sized complexes with nega-
tively charged ONs, which are efﬁciently internalized by
cells presumably via an endocytosis-dependant mechanism
(15,18,18,19). The non-covalent complexation strategy has
the advantage of avoiding laborious chemical conjugation
of the CPP with its cargo. Moreover, it was found that
lower concentrations of ONs are generally required to
achieve a biological response utilizing the non-covalent
complexation (17,19). However, one limitation of this
strategy is that much of the delivered cargo becomes
entrapped in endosomes following endocytosis.
Therefore, several chemical modiﬁcations have been intro-
duced into CPPs to enhance endosomal escape (19).
N-terminal stearic acid modiﬁcation was shown to
enhance both the complexation capacity and endosomal
escape properties of certain CPPs (19,20). It has been
shown previously by our group that the stearic acid-
modiﬁed CPPs, stearyl-TP10 (21) and stearyl-(RxR)4
(17), are able to transfect cells with PS-20-OMe SCOs .
However, a drawback with the above-mentioned peptides
is that they are generally less efﬁcient than commercial
lipid-based vectors such as LF2000, and relatively inefﬁ-
cient at transfecting cells in the presence of serum proteins.
Although CPPs have been extensively studied as drug
delivery vectors, formulation of CPP-based therapeutics
into different pharmaceutical forms has never been given
the same attention. Pharmaceutical formulation has
always a major inﬂuence on the efﬁciency and stability
of active pharmaceutical ingredients. In addition, each
therapeutic application requires its own pharmaceutical
form. Therefore, developing different formulations for
CPP-based therapeutics could have great implications on
their activity and stability, besides, broadening the range
of therapeutic applications that CPPs could be utilized in.
Particularly, solid formulation is the most widely used
pharmaceutical form. It is used in tablets, capsules,
sustained-release formulations, powders for inhalation
and powders for injection. In addition, solid formulations
are the most stable forms upon storage and transport.
Thus, from a translational perspective, it would be of
great importance to be able to formulate CPP-based
therapeutics as solid form.
Here, we describe a new stearylated CPP that we desig-
nate PepFect 14 (PF14). It is a modiﬁed version of our
previously reported peptide, stearyl-transportan10
(stearyl-TP10) (21), where we utilized ornithines and
leucines instead of lysines and isoleucines. PF14 demon-
strates remarkable splice-correction activity in two differ-
ent cell models including mdx mouse myotubes, a cell
culture model of DMD, even in the presence of serum.
Furthermore, the feasibility of formulating these nano-
complexes into solid formulation was investigated and
the efﬁciency and stability of such formulations were
assessed. Remarkably, the solid formulations obtained
upon drying the nanocomplexes over soluble excipients
were as active as the freshly prepared counterpart even
when stored at elevated temperatures for several weeks.
MATERIALS AND METHODS
Oligonucleotide and peptide synthesis
PS-20-O-methyl RNA ON (Table 1) was synthesized on
an A ¨ KTA
TM oligopilot
TM plus 10 synthesizer with
Oligosynt
TM 15 (GE Healthcare, Sweden) pre-packed syn-
thesis columns as previously described (22). For
50-labeling, a molar excess of 10 equivalents Cy5-amidite
(GE Healthcare, UK) at 0.1 M was used and Cy5-amidite
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by anion-exchange chromatography and desalting fol-
lowed by anion-exchange high-performance liquid chro-
matography (HPLC) and mass analysis as previously
described (22). The molarity of ONs was determined by
measurements of optical density at 260nm. The PS-20-O-
Me RNA ON for mdx mouse myotubes (Table 1) with
sodium counterions was obtained from RiboTask (23).
PF14 (Table 1) was synthesized (SYRO multiple peptide
synthesizer, MultiSynTech, Germany) on Fmoc-Rink-
amide-4-methylbenzhydrylamine resin (0.67mmol/g,
IRIS Biotech, Germany) using standard Fmoc solid-phase
peptide synthesis (24). Stearic acid (Sigma-Aldrich)
was coupled to the N-terminus by using TBTU/HOBt
[2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
tetraﬂuoroborate/1-hydroxybenzotriazole] (IRIS Biotech,
Germany) activation in dimethylformamide/dichloro-
methane. The peptide was cleaved using 95% TFA/2.5%
water/2.5% triisopropylsilane for 3h and precipitated in
diethylether. The obtained crude peptide was dried in
vacuum overnight. The peptide was puriﬁed by HPLC
on a Discovery C-18 Supelco column (Sigma-Aldrich,
Sweden) using a gradient of acetonitrile/ water containing
0.1% TFA. The identity of the puriﬁed product was
veriﬁed by analytical HPLC and by Perkin Elmer
prOTOF
TM 2000 matrix-assisted laser desorption ioniza-
tion time-of-ﬂight mass spectrometer (Perkin Elmer,
Sweden). The mass-spectrum was acquired in positive
ion reﬂector mode using a-cyano-4-hydroxycinnamic
acid as a matrix (Sigma-Aldrich) (10mg/ml, 7:3 acetoni-
trile: water, 0.1% TFA). The molarity of the peptide was
determined based on dilutions of accurately weighed
substances.
Cell culture
HeLa pLuc705 cells, kindly provided by Prof. R. Kole,
and U2OS cells were grown at 37 C, 5% CO2 in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) with
glutamax supplemented with 0.1mM non-essential
amino acids, 10% fetal bovine serum (FBS), 200U/ml
penicillin and 200mg/ml streptomycin (Invitrogen,
Sweden). Mdx mouse myotubes were obtained from con-
ﬂuent H2K mdx cells seeded in gelatin-coated 24-well
plates following 2 days of serum deprivation (DMEM
with 5% horse serum) (25). More information regarding
cell culture and myotubes development can be found in
Supplementary Figure S1.
Splice-correction assay
HeLa pLuc705 cells (5 10
4) were seeded 24h prior to ex-
periments into 24-well plates. PS-20-OMe SCOs were
mixed with PF14 at different molar ratios (MRs) in
MQ-water in 10% of the ﬁnal treatment volume (i.e.
50ml). Complexes were formed for 1h at room tempera-
ture and meanwhile the cell medium was replaced in the
wells with fresh serum-free or serum-containing DMEM
media (450ml). Thereafter, complexes were added
to each well. When using LF2000, Oligofectamine,
Lipofectamine
TM RNAiMAX (Invitrogen, Sweden) and
jetPEI (Polyplus transfection, In Vitro, Sweden), the
complexes were prepared according to the manufacturer’s
protocol. Cells were treated with PF14-SCO nano-
complexes at different MRs (3:1, 5:1, 7:1, 10:1, 20:1) for
4h in serum-free medium (or in serum-containing media)
followed by addition of serum to a ﬁnal concentration of
10% (only to cells grown in serum-free medium) and
incubated for additional 20h. Thereafter, the cells were
lysed using 100ml 0.1% Triton X-100 in
HEPES-buffered Krebs Ringer (HKR) buffer for 30min
at room temperature. Luciferase activity was measured
using Promega’s luciferase assay system on
GLOMAX
TM 96 microplate luminometer (Promega,
Sweden) and normalized to protein content determined
using the Lowry method (BioRad, USA). In experiments
with chloroquine, after complex formation and prior to
treatment of cells, chloroquine (ﬁnal concentration
100mM) was added to the transfection mixture in order
to promote endosomal escape. Four hours after addition
of the nanocomplexes and chloroquine to cells, cell
medium was replaced with fresh medium in order to
avoid the toxic effects of chloroquine. In experiments as-
sessing the impact of temperature on splice correction,
cells were kept for 30min at 37 or 4 C prior to addition
of PF14-SCO complexes. Cells were treated for 1 h,
washed twice with PBS and cultivated back at 37 C for
additionally 20 h. For experiments with mdx mouse
myotubes, PF14 nanocomplexes at different MRs were
prepared as mentioned above and incubated with
myotubes for 4h in 0.5ml OptiMEM or in DMEM/10%
FBS. ONs complexed with Lipofectamine 2000 in
OptiMEM according to the manufacturer’s protocol,
were also incubated with myotubes in OptiMEM as a
control. The media in all cases was replaced by 1ml of
DMEM/5% horse serum media for further incubation.
Reverse-transcription PCR
For the HeLa pLuc705 cell-line, cells were trypsinized and
total RNA was isolated from the cell pellets using the
RNeasy plus kit (QIAGEN, Sweden). The quality of
RNA was veriﬁed by agarose gel electrophoresis. Three
nanogram of RNA were used in each reverse-transcription
PCR (RT–PCR) reaction in which the total volume was
20ml using the ONE STEP RT–PCR kit (QIAGEN). The
primers had the following sequences: Fwd-50-TTGATAT
GTGGATTTCGAGTCGTC-30; Rev-50-TGTCAATCAG
AGTGCTTTTGGCG-30. The program for the RT–PCR
was as follows: 55 C, 35min, then 95 C, 15min, for
reverse transcription step directly followed by the PCR
Table 1. Sequences of PF14 and PS-20-O-methyl oligoribonucleotides
Name Sequence
PF14 Stearyl- AGYLLGKLLOOLAAAALOOLL-NH2
PF14 A AGYLLGKLLOOLAAAALOOLL-NH2
SCO for HeLa
pLuc705 cells
50-CCU CUU ACC UCA GUU ACA
SCO for mdx
mouse myotubes
50-GGCCAAACCUCGGCUUACCU
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and ﬁnally 72 C, 10min, for ﬁnal extension. The PCR
products were analyzed in a 2% agarose gel in 1 TBE
buffer and visualized by SYBR Gold (Invitrogen,
Molecular Probes) staining. Gels were documented using
the Fluor-S system with a cooled CCD camera (BioRad)
and analyzed with the Quantity One software (BioRad).
For the mdx mouse myotubes, 24h after transfec-
tion myotubes were washed twice with PBS and total
RNA was extracted with 0.5ml of TRI Reagent (Sigma).
RNA preparations were treated with RNase
free DNase (2U) and Proteinase K (20mg) prior to
RT–PCR analysis. RT–PCR was carried out in 12.5ml
with 0.5mg RNA template using SuperScript III
One-Step RT–PCR System with Platinum Taq DNA poly-
merase (Invitrogen) primed by forward primer 50-CAG
AAT TCT GCC AAT TGC TGAG-30 and reverse
primer 50-TTC TTC AGC TTG TGT CAT CC-30. The
initial cDNA synthesis was performed at 55 C for
30min followed by 30 cycles of 95 C for 30 s, 55 C for
1min and 68 C for 80s. RT PCR product (1ml) was then
used as the template for secondary PCR performed in
25ml with 0.5U Super TAQ polymerase (HT
Biotechnologies) and primed by forward primer 50-CCC
AGT CTA CCA CCC TAT CAG AGC-30 and reverse
primer 50-CCT GCC TTT AAG GCT TCC TT-30. The
cycling conditions were 95 C for 1min, 57 C for 1min
and 72 C for 80 s for 25 cycles. Products were examined
by 2% agarose gel and after scanning using Gene Tools
Analysis Software (SynGene), the relative amount of exon
23 skipping was expressed as a percentage at a given con-
centration of conjugates averaged over duplicates of three
experiments.
Fluorometry and live-cell confocal imaging
HeLa pLuc705 cells (5 10
4) were seeded 24h before the
experiment in 24-well plates. PF14-Cy5-labeled SCO
nanocomplexes (MR5, 200nM SCO) were added to the
cells in 500ml serum-free medium for 4h followed by the
addition of serum to a ﬁnal concentration of 10% and
incubated for additional 20h. Cells were washed twice in
HKR buffer and trypsinized for 10min with 0.25%
trypsin (Invitrogen, Sweden). Cells were then centrifuged
at 1000g for 5min at 4 C, and cell pellets were lysed in
250ml 0.1% Triton X-100 in HKR buffer for 1h, after
which 200ml lysate was transferred to a black 96-well
plate. Fluorescence was measured at 650/670nm on
FlexStation II ﬂuorescence reader (Molecular devices,
USA) and the amount of internalized compound was
normalized to the amount of protein was determined
using the Lowry method (BioRad, USA). In experiments
where splice-correction was measured simultaneously,
luciferase activity was measured as mentioned above for
the same cell lysate. For live cell confocal imaging micros-
copy studies, a number of 3.6 10
4 U2OS cells were
seeded in an 8-well IBItreatm-Slide (IBIDI; LRI instru-
ments AB; Stockholm, Sweden), the day before the experi-
ment. PF14-Cy5-labeled SCO complexes (MR5, 100nM
SCO) and 5mM of 10 KDa A488-Dextran (Molecular
Probes, Invitrogen) were added to the cell medium and
co-incubated for 3 h. Cells were then washed extensively
with 1 HBSS and ﬁnally 300ml of OptiMEM without
phenol red (Invitrogen) was added. Live cell imaging
was then performed using a Zeiss LSM 510 confocal
microscope equipped with a Plan-Apochromat 63 /1.4
oil DIC objective with a 0.8 aperture. Images were
analyzed and prepared with Zeiss LSM image browser
or ImageJ (when imageJ was used the function despeckle
was utilized to reduce noise in the image)
Cell proliferation Wst-1
Cell proliferation was assessed by the Roche Wst-1 prolif-
eration assay according to the manufacturer’s instruc-
tions. Brieﬂy, 1 10
4 cells were seeded 1day prior to the
experiment on a 96-well plate. Cells were treated with
PF14-SCO nanocomplexes at different MRs for 4h in
serum-free medium followed by the addition of serum to
a ﬁnal concentration of 10% and incubated for additional
20 h. LF2000 was used according to the manufacturer’s
protocol in serum-free conditions utilizing the same SCO
dose. Wst-1 was added according to the manufacturer’s
protocol (Roche Diagnostics Scandinavia AB, Sweden).
Wst-1 measures the activity of the mitochondrial dehydro-
genases to convert tetrazolium salts to formazan and
cell proliferation is directly correlated to the amount of
formazan dye that is formed. Absorbance was measured
at 450nm on Digiscan absorbance reader (Labvision via
AH Diagnostics AB, Sweden). The percentage of viable
cells was determined by normalizing the values obtained
for treated cells with untreated cells.
Solid dispersion
Excipient solutions of lactose monohydrate (Merck
Chemicals, Germany), mannitol (Duchefa Biochemie,
Holland) and PEG 6000 (Sigma-Aldrich, Sweden) were
prepared at ﬁnal concentration of 100mg/ml in MQ
water. PF14-SCO nanocomplexes (MR5, 200nM) were
prepared in 5% of the ﬁnal treatment volume (i.e. 25ml).
After complexation, different proportions of the excipient
solutions were added to the ﬁnal concentrations of 1.67,
3.33 and 5% solubilized excipient in the reaction mixture.
The mixture was thereafter dried in Savant DNA
speed-vac (model DNA 120–230) for 2h, during which
the temperature ranged between 55 and 60 C. Before
transfection, the dried powder was reconstituted in 50ml
of MQ water and added to cells grown in 450ml of serum-
containing medium and incubated for 24h. LF2000
complexes were prepared according to manufacturer’s
protocol. Subsequently, the same proportions of the ex-
cipient solutions utilized for PF14 formulation were
added, and then the mixture was dried and reconstituted
similarly. Luciferase activity was measured as stated
earlier.
Dynamic light scattering and zeta potential studies
Hydrodynamic mean diameter of the nanocomplexes was
determined by dynamic light scatter (DLS) studies using a
Zetasizer Nano ZS apparatus (Malvern Instruments, UK).
PF14-SCO nanocomplexes, freshly prepared in solution or
in solid dispersion (SD) formulations, were prepared
Nucleic Acids Research, 2011,Vol.39, No. 12 5287according to the protocols for transfection and diluted in
Opti-MEM with 10% serum into a ﬁnal volume of
500ml. Samples were assessed in disposable low-volume
cuvettes. All data was converted to ‘relative intensity’
plots from where the mean hydrodynamic diameter was
derived.
ZetapotentialwasmeasuredinOptiMEMsupplemented
with 10% FCS or in 0.01mM KCl. Measurements were
performed utilizing the abovementioned instrument, set
to automode and a number of ﬁve runs.
Stability study
Lactose solid dispersion formulations at a concentration
of 3.33% were prepared according to the protocol for
transfection and stored either at room temperature or in
ovens of adjusted temperatures (40 and 60 C). Samples
were monitored for 8 weeks and tested at 0, 2, 4 and
8 weeks time points.
Statistics
Values in all experiments are represented as mean±SEM
of at least three independent experiments done in dupli-
cate. Differences were considered signiﬁcant at *P<0.05
using two-tailed Student’s t-test.
RESULTS
PF14 efﬁciently induces SCO-mediated splice-correction
in serum-free and serum-containing media in HeLa
pLuc705 cell model
To screen for the most optimal peptide-SCO ratio for
splice-correction activity, PF14-SCO complexes were
formed at different MRs. MR 3, 5, 7 and 10 were tested
in serum-free medium and MR 3, 5, 10 and 20 were tested
in serum-containing medium with dose titrations using
200, 100 or 50nM SCO. LF2000 was used as positive
control in all experiments according to manufacturer’s
protocol utilizing the highest dose (200nM SCO). The
assay we used is based on the HeLa pLuc705 cell-line
stably transfected with a luciferase-encoding gene inter-
rupted by a mutated b-globin intron 2. This mutation
causes aberrant splicing of luciferase pre-mRNA resulting
in the synthesis of non-functional luciferase (26). Masking
the aberrant splice site with PS-20-OMe SCO redirects
splicing towards the correct mRNA and consequently
restores luciferase activity. We found that splice-
correction was induced in a dose-dependent manner at
all the tested MRs and using MR5 resulted in the
highest splice-correction activity in both types of media.
Remarkably, in serum-free medium, PF14 at MR5
exceeded LF2000 by several times (Figure 1A).
Interestingly, in serum-containing medium, PF14 at
MR5 was capable of retaining >75% of its activity
observed in serum-free conditions, and also signiﬁcantly
surpassing LF2000 (Figure 1B).
EC50 and kinetics of PF14-SCO mediated
splice-correction
Next, RT–PCR was conducted to assess the EC50 of PF14
nanocomplexes. EC50 is the concentration of SCO at
which 50% splice-correction occurs. It is a very important
parameter in the characterization of a delivery vector,
because it allows direct comparison of the efﬁciencies of
different vectors tested using the same model. RT–PCR
was utilized to detect the quantity of corrected full-length
luciferase mRNA after dose titration with different SCO
concentrations complexed with PF14 at MR5. We found
that PF14-SCO nanocomplexes have very low EC50 values
( 100nM) in both serum-free and serum-containing
medium (Figure 2A).
In order to assess the kinetics of splice-correction, cells
were transfected with PF14 at MR5 using 200nM SCO
and then the percent of splice-correction was monitored
over a time interval ranging from 2h to 48 h. More than
60% splice-correction was observed already after 8h
(Figure 2B). This shows that, although PF14 forms
stable and highly active nanocomplexes with SCOs, the
SCO cargo is released quickly inside the cells resulting in
an early onset of the biological activity. The splice-
correction activity reached its peak after 24h before it
started to decline within 48h (Figure 2B).
PF14 efﬁciently induces SCO-mediated splice-correction
in serum-free and serum-containing media in differentiated
mdx mouse myotubes
The leading cell-model system for development of drugs
and drug delivery systems for treatment of DMD is the
H2K mdx mouse myotubes, which carries a point
mutation in exon 23 of the dystrophin gene (25). PF14-
SCO nanocomplexes at MR5 (Figure 3A and B) or MR7
(Figure 3C) were incubated with mouse mdx muscle cells
at various concentrations in the presence or absence of
10% FBS. Signiﬁcant amounts of exon skipping were
observed, which increased in a concentration-dependent
manner. For MR5, the levels were as good as treatment
with the same concentration of SCO using LF2000, both
in OptiMEM (serum-free conditions), and at MR7, PF14
was higher than LF2000 (Figure 3B and C). The effect of
added 10% FBS was small on exon skipping at both MRs
and especially at MR7, showing that PF14 activity is not
substantially affected by serum.
PF14-SCO nanocomplexes are internalized via
endocytosis
Subsequently, Cy5-labeled SCOs were used to determine
the relation between the quantity of SCOs taken up by the
cells and the biological activity. PF14 mediated uptake of
Cy5-labeled SCO in a dose-dependent manner, which was
congruent to the splice-correction data obtained simultan-
eously (Figure 4A). However, in the presence of chloro-
quine, the splice-correction activity increased, while the
uptake remained nearly unchanged. This discrepancy
between uptake and biological activity in the presence of
chloroquine, a well-known endosomolytic agent, suggests
the involvement of endocytic vesicles in the uptake of the
nanocomplexes. Endocytic uptake was further supported
by the signiﬁcant decrease in activity after incubation at
4 C which is known to inhibit energy-dependant uptake
mechanisms like endocytosis (Figure 4B). To further
corroborate these results, live cell confocal imaging
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SCO nanocomplexes together with labeled dextran were
co-incubated with U2OS cells and extensive co-
localization was observed (Figure 4C). Similar pattern
was also seen in the A549 cell-line (Supplementary
Figure S3). In addition, ﬂow-cytometry analysis was
carried out to assess the percentage of cells being trans-
fected. In keeping with the high splice-correction activity,
we found that PF14 transfected nearly the entire cell popu-
lation (Supplementary Figure S4).
PF14 induces SCO-mediated splice-correction in a
conﬂuence-independent and non-toxic manner
It is a well-known fact that many commercial transfection
reagents, such as LF2000, are strictly dependent on certain
cell densities for optimal performance. To assess the effect
of cell conﬂuency, transfections were carried out at differ-
ent cell densities (2.5 10
4,5 10
4,1 0 10
4 and 20 10
4
cells/well), comparing PF14 with LF2000. As shown in
Figure 5A, PF14-SCO complexes appeared less sensitive
Figure 1. Splice-correction activity of PF14- SCO nanocomplexes in HeLa pLuc705 cell-line. HeLa pLuc705 cells (5 10
4) were seeded 24h prior to
experiments into 24-well plates. Cells were treated with PF14-SCO nanocomplexes at three different concentrations at MRs (3:1, 5:1, 7:1 and 10:1)
for 4h in serum-free medium followed by addition of serum to ﬁnal concentration of 10% and incubated additionally for 20h (A), and at MRs (3:1,
5:1, 10:1 and 20:1) for 24h in serum-containing medium (B). The controls used were: stearyl-TP10 (MR5, 200nM), PF14 A (unstearylated PF14,
Table 1) at MR5 and 200nM dose, PF14 only (1mM) and P14-unrelated ON (MR5, 200nM). LF2000 was used according to the manufacturer’s
protocol using the highest SCO concentration (200nM). Cells were lysed in 0.1% Triton X-100 and luciferase activity was measured.
Splice-correction assay results are presented as fold-increase over untreated cells (control). The values represent the mean of at least three experiments
performed in duplicate (mean±SEM, n=3). Intergroup differences were considered signiﬁcant at *P<0.05 using Student’s t-test.
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progressively lost its activity as the cell number increased.
In order to exclude that the high transfection efﬁciency
observed with PF14 was associated with increased cyto-
toxicity, the activity of mitochondrial dehydrogenases was
measured as an indicator of healthy, metabolically active
cells using the Wst-1 assay. Even under serum-free condi-
tions (Figure 5B), PF14-SCO complexes had no effect on
cell viability, whereas LF2000 induced signiﬁcant impair-
ment of metabolic activity; a well-known problem of
lipid-based ON complexes (lipoplexes) (13).
PF14-SCO nanocomplexes can be formulated into solid
form by solid dispersion technique
To investigate the possibility of formulating PF14-SCO
nanocomplexes into solid formulation, we adopted the
solid dispersion technique. This technique was used to
obtain uniform distribution of the nanocomplexes over
hydrophilic solid matrices. Mannitol, lactose and PEG
6000 were used as excipients at various concentrations:
1.67, 3.33 and 5 % solubilized excipient in the reaction
mixture (referred to as low, medium and high concentra-
tions of excipient, respectively, Figure 6). For drying, we
used heating to 55–60 C under vacuum. We found that,
after resuspension and addition to the cells, the solid for-
mulations were remarkably efﬁcient at inducing splice-
correction at rates comparable to the freshly prepared
nanocomplexes in solution (Figure 6). Actually, lactose
solid dispersion at a concentration of 3.33% (lactose-SD
3.33%) mediated splice-correction activity almost identi-
cal to the freshly prepared nanocomplexes. Mannitol solid
dispersions displayed slightly lower values, while PEG
Figure 2. EC50 and kinetics of PF14 SCO nanocomplexes. (A) The concentration of SCO at which 50% splice-correction occurred is referred to as
EC50. HeLa pLuc705 cells were transfected with different concentrations of SCO (25–200nM) formulated with PF14 at MR5. The control, unrelated
ON was used at the highest concentration tested (200nM). Splice-correction was evaluated by measuring the corrected mRNA levels after running
RT–PCR. (i) Splice-correction induced by different concentrations of the SCO. Cells were transfected with PF14 nanocomplexes in either serum-free
medium (without serum) or in serum-containing medium (with serum) according to the transfection protocol stated earlier. Splice-correction was
calculated as the percentage (percent splice-correction) of the corrected luciferase band to the sum of corrected and aberrant bands. (ii) Levels of
corrected mRNA were quantiﬁed in 2% agarose gel using the Quantity One software. Gels are for nanocomplexes with PF14 without serum (top)
and PF14 with serum (bottom). Lanes are as follows: 200nM SCO, 100nM SCO, 50nM SCO, 25nM SCO, 200nM unrelated SCO (UR)
and untreated cells (UT). The upper band in each gel represents the aberrant luciferase mRNA and the lower band is for the corrected form.
(B) (i) Kinetics of splice-correction in HeLa pLuc705 cells. The SCO was complexed with PF14 at MR5. Final concentration of the SCO in each well
was 200nM. Transfections were performed in either serum-free (without serum) or serum-containing (with serum) media. (ii) Gels are for complexes
with PF14 without serum (top) and PF14 with serum (bottom). Lanes are as follows: 2, 4, 8, 12, 16, 24, 48h and untreated cells (UT).
5290 Nucleic Acids Research, 2011,Vol.39, No. 126000 solid dispersions demonstrated the highest deviation
from the values obtained using the freshly prepared nano-
complexes (Figure 6). In contrast, applying the same pro-
cedure on LF2000 nearly eliminated any residual activity.
On the contrary, the high residual activity of PF14 formu-
lations suggests that the PF14 nanocomplexes remain
intact after drying and dispersion under these conditions.
DLS analysis and zeta potential measurements of
PF14-SCO nanocomplexes
To conﬁrm the presence of intact nanocomplexes in the
formulations, DLS studies and zeta potential measure-
ments were performed. These assessments were conducted
in the presence of serum to allow possible correlations
between such parameters and transfection activity at
physiological conditions. Serum contains a number of
proteins and protein aggregates that will scatter light re-
sulting in a population of particles independent of the
PF14-SCO nanocomplexes and can also affect the zeta
potential by surface adsorption of some serum proteins.
However, we believe that although the presence of serum
will affect such measurements, these conditions are more
relevant to the physiological ones. For DLS, we have
compared the populations detected in serum-containing
medium alone and after addition of PF14-SCO nano-
complexes. It was possible to distinguish the constant
protein aggregates (inherent to the serum, and >100nm)
and a completely independent population associated to
the PF14 nanocomplexes (data not shown). Due to the
presence of serum proteins, the polydispersity index
(PdI) of the solution containing the nanocomplexes does
not describe the homogeneity of the PF14 nanocomplexes
alone. For this reason, we refer to the shape of the curves
that characterize the different populations while eval-
uating the homogeneity of the particles. For zeta poten-
tial, measurements were carried out either in 0.01mM KCl
or in the presence of 10% serum. After resuspension of the
solid formulations, DLS measurements showed that nano-
complexes are present in all the tested formulations.
However, the uniformity of particles size distribution
and the extent of similarity in relation to the freshly
prepared nanocomplexes differed with different excipients.
Lactose-SD 3.33% formulations were most homoge-
neous and most similar to the distribution pattern of the
freshly prepared nanocomplexes in solution (Figure 7 and
Table 2). These results go in accordance with the transfec-
tion results where lactose-SD 3.33% displayed the highest
splice-correction activity. Moreover, this analysis demon-
strates that different excipients affect the physicochemical
characterizes of the nanocomplexes differently in terms
of particle size and uniformity, and this effect is reﬂected
on the biological activity. We studied the surface charge
(zeta potential) of the PF14 nanocomplexes, both freshly
prepared and after drying at 50–60 C in the solid disper-
sion procedure. Interestingly, independent of formula-
tion type and media (presence or absence of serum),
the nanocomplexes displayed negative surface charges
(Table 2).
Solid dispersion formulations are stable for several weeks
at elevated temperatures
Finally, we tested the stability of the best-performing for-
mulation, lactose-SD3.33%, when stored for 2 months at
an elevated temperatures. The formulations were stored at
three different temperatures (RT, 40 and 60 C) and
sampled over an 8 weeks period. We found that the
tested formulations were remarkably stable. There was
no statistically signiﬁcant loss in transfection efﬁciencies
at any time-point except for the 60 C 8-weeks point where
the transfection efﬁciency decreased to 70% of the initial
value (Figure 8). Compared to lyophilized lipoplexes
(27,28), PF14 formulations demonstrated an excellent
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Figure 3. Splice-correction activity of PF14-SCO nanocomplexes in mdx
mouse myotubes. (A) RT–PCR analysis to measure exonskipping activity
of PF14-SCO nanocomplexes in mdx mouse myotubes at three different
concentrations, at MR5 in serum-free OptiMEM and DMEM/10% FBS
in comparison with control LF2000 transfection in OptiMEM. Exon
skipping activity was measured as the amount of RT–PCR product
after treatment of cells with PF14-SCO nanocomplexes at MR5 (B)o r
MR7 (C) at three different concentrations. The values represent the mean
of at least three independent experiments performed in duplicate
(mean±SEM, n=3).
Nucleic Acids Research, 2011,Vol.39, No. 12 5291stability proﬁle without further additives or special storage
conditions.
DISCUSSION
Several vectors have been utilized to enhance the delivery
of ONs. Cationic liposomes have been extensively studied
for this purpose; however, despite demonstrating high
activity, the associated toxicity has hindered their
progress into clinical applications (13). Alternatively,
CPPs have been shown to deliver a wide variety of
nucleic acid-based therapeutics intracellularly, including
SCOs and siRNA (14,29). CPPs covalently conjugated
to SCOs have been shown to induce splice-correction
activity in different models (7,16). However, this strategy
entails laborious chemical conjugation procedures (19). In
addition, high doses of the SCO are required to induce
signiﬁcant biological response (17). On the other hand,
some CPPs have shown to be able to deliver ONs utilizing
a non-covalent complexation strategy, especially when
chemically modiﬁed with fatty acids (18,20). We have
demonstrated earlier that the stearylated versions of
TP10 (21) and (RXR)4 (17) show enhanced ability to
deliver SCOs and plasmids into cells upon non-covalent
Figure 4. Uptake of Cy5-labeled SCO, effect of lowering temperature and live cell confocal imaging. (A) HeLa pLuc705 cells (5 10
4) were seeded
24h prior to experiments into 24-well plates. Cells were treated with PF14-Cy5-lebeled SCO nanocomplexes at MR5 at three different concentrations
for 4h in serum-free medium followed by the addition of serum to a ﬁnal concentration of 10% and incubated for additional 20 h. For the
chloroquine-treated wells, 100mM chloroquine was added to the complexes prior to cell treatments. Cells were washed with HKR buffer, trypsinized
and centrifuged at 1000g. Pellets were lysed in 0.1% Triton X-100 in HKR buffer and ﬂuorescence was measured at 650/670nm. (i) Fluorescence was
recalculated to pmol internalized Cy5 SCO per mg protein. (ii) Luciferase activity was measured for the same cell lysate. The values represent the
mean of at least two independent experiments performed in triplicate (mean±SEM, n=3). Intergroup differences were considered signiﬁcant at
*P<0.05 using Student’s t-test. (B) HeLa pLuc 705 cells (5 10
4) were seeded 24h prior to experiments into 24-well plates. Thirty minutes prior
treatment of cells with 50 or100nM PF14-SCO (MR5) in serum or serum-free media, cells were incubated at 4 or 37 C. Cells were treated for 1h at
indicated temperatures and washed twice with PBS before being placed back at 37 C for additionally 20 h. Cells were processed and analyzed as in
the chloroquine experiements. (C) PF14-Cy5-SCO complexes and 10kDa A488-Dextran were co-incubated with U2OS cells. A major co-localization
is seen overall, presented by the appearance of yellow colored vesicles (co-localization of green marked Dextran and red marked PF14-SCO
nanocomplexes). The white arrows point out some pre-eminent co-localization vesicles. Several Z-slices per image were taken which allowed us to
conﬁrm the co-localization both in X, Y and Z plane in more detail. Such an example is given by the intersection of the green/red (X, Y plane; main
picture) and green/blue (Z sectioning panel inserted to the right) or red/blue (Z plane sectioning inserted in the top) lines. The ﬂuorescence imaging was
overlaid on top of the differential interference contrast image (DIC) in order to have a relative view of the cell together with the labeled vesicles.
5292 Nucleic Acids Research, 2011,Vol.39, No. 12complexation. In contrast to other CPPs that are predom-
inantly entrapped in endosomal vesicles after internaliza-
tion, the remarkably enhanced splice-correction observed
with stearyl-TP10 and stearyl-(RXR)4 was mainly due to
more efﬁcient endosomal escape (17,21). However, despite
being less toxic than lipid-based vectors such as LF2000,
these peptides are generally less efﬁcient. Moreover, most
transfection reagents are highly active in serum-free con-
ditions, but show considerable decrease in their efﬁciency
in the presence of serum. This is important, since it
immediately suggests that they are less likely to perform
well in vivo.
In the current work we present a new chemically
modiﬁed CPP, PF14. Starting from stearyl-TP10, we
utilized ornithines as the main source of positive charges
instead of lysines. The design of this peptide was based on
earlier reports showing that poly-L-ornithine demon-
strated superior transfection efﬁciency (up to 10-fold)
compared to equivalent poly-L-lysine-based systems (30).
The superior efﬁciency of poly-L-ornithines was related to
Figure 5. Cell conﬂuency dependence and cytotoxicity. (A) HeLa pLuc705 cells seeded at indicated densities 1day prior to the experiment were
treated with 200nM SCO with either PF14 MR5 or LF2000. (B) Cells were exposed to PF14 (MR5, SCO 200nM) complexes for 4h in serum-free
medium, followed by addition of serum to a ﬁnal concentration of 10% and incubated for additional 20 h. LF2000 was used according to the
manufacturer’s protocol in serum-free conditions with the same SCO dose. Splice-correction assay results are presented as fold-increase untreated
cells (control). Toxicity was assessed by Wst-1 assay. The values represent the mean of at least three independent experiments performed in duplicate
(mean±SEM, n=3). Intergroup differences were considered signiﬁcant at *P<0.05 using Student’s t-test.
Nucleic Acids Research, 2011,Vol.39, No. 12 5293the higher afﬁnity for DNA and the ability to make more
stable complexes at lower charge ratios (30). Furthermore,
we hypothesized that ornithine, being a nonstandard
amino acid, would be less prone to serum proteases, and
thus could retain the activity in serum conditions.
Upon screening for the most optimal MR in the HeLa
pLuc705 cell model, we found that MR5 displayed the
highest activity in serum-free and serum-containing
media (Figure 1). Importantly, in contrast to all tested
CPPs so far, PF14 displayed higher activity than
LF2000 even in the presence of serum. PF14 activity
also exceeded that of Oligofectamine
TM, RNAiMAX
TM
and jetPEI
TM (Supplementary Figure S2). When used at
the same concentration, stearyl-TP10 imparted modest
activity compared to PF14, which demonstrates the
importance of the new modiﬁcations (Figure 1). Also,
removal of the stearyl group abolished the activity
entirely (Figure 1), emphasizing the role of such a lipo-
philic moiety. On the mRNA level, PF14-SCO nano-
complexes had a very low EC50 value of  100nM in
both types of media (Figure 2A). Compared to other
reported CPPs such as Pip1, RXR4 and R6Pen covalently
linked to splice correcting PNA (7), PF14-SCO nano-
complexes had at least ﬁve times lower EC50 values.
These results add to the evidence that non-covalent com-
plexation imparts biological activity at lower ON concen-
trations. Kinetics studies showed early onset of activity.
Figure 6. Solid formulation development and excipient screening. Excipient solutions of lactose, mannitol and PEG 6000 were prepared at ﬁnal
concentration of 100mg/ml in MQ water. PF14-SCO nanocomplexes were prepared in 25ml MQ water for 1 h, then different proportions of the
excipient solutions were added to the ﬁnal concentrations of 1.67% (low), 3.33% (medium) and 5% (high) solubilized excipient in the reaction
mixture. The mixture was then dried in speed-vac for 2 h, during which the temperature ranged between 55 and 60 C. Before transfection, the dried
powder was reconstituted in 50ml of MQ water and added to the wells. LF2000 complexes were prepared according to manufacturer’s protocol.
Subsequently, the same proportions of the excipient solutions utilized for PF14 formulation were added, and the mixture was dried and reconstituted
similarly. HeLa pLuc705 cells (5 10
4) were treated with reconstituted complexes for 24h in serum containing medium. Cells were then lysed in 0.1%
Triton X-100 and luciferase activity was measured. The results from splice-correction assay of different formulations of PF14 and LF2000 are
presented as fold-increase over untreated cells (control).
Figure 7. Dynamic light scattering (DLS). Average diameter of the
particles formed by the different formulations studied. Particle size
distribution was assessed by dynamic light scatter. All samples were
measured in triplicates. The ﬁgure shows representative curves of the
populations’ distribution in relation to intensity of the scattered light.
All formulations were used at the concentration of 3.33%.
Table 2. Average diameter of the population of complexes in
0.01mM KCl or in the presence of 10% serum
Samples Average
diameter (nm)
Zeta
potential (mV)
in 0.01mM KCl
Zeta
potential (mV)
in OptiMEM
10% FCS
Freshly prepared 363.8±52  28.4±3.79  12.1±1.41
Mannitol 156.9±43.7  15.4±6.31  14.2±1.64
Lactose 298±57.7  16.4±4.37  10.4±2.06
PEG 6000 208.3±76  17.7±1.72  9.94±2.55
Average peak is presented in nm (STD). All solid dispersion formula-
tions were used at the concentration 3.33%.
5294 Nucleic Acids Research, 2011,Vol.39, No. 12More than 60% splice-correction was achieved as early as
8h after transfection. This demonstrates that, despite
being very stable, the nanocomplexes are rapidly dis-
sociated inside the cells releasing SCO cargo. However,
natural decline in the signal takes place after 48h as the
nanocomplexes become more dilute due to degradation
and cell division (31). In line with the above-mentioned
reports (30), our results suggest that ornithine forms very
stable nanocomplexes that are more resistant to cellular
and serum proteases enabling PF14 to mediate very high
levels of splice-correction much more efﬁciently than its
predecessor; stearyl TP-10.
To demonstrate the activity of PF14 in a disease-
relevant model, we used mdx mouse myotubes, a model
for DMD. Remarkably, PF14 nanocomplexes were able
to induce signiﬁcant levels of splice-correction exceeding
LF2000 at MR7 (Figure 3C). Compared to other
peptide-based vectors tested in the same model, PF14 is
signiﬁcantly more active reaching saturation of the cor-
rected band signal at doses ranging from 250nM for
MR5 and 200nM for MR7, which is several folds lower
than doses in the micromolar range used for other vectors
(7). Additionally, PF14 effect was not substantially
affected in the presence of serum.
To quantify the efﬁciency of uptake of SCOs by PF14,
ﬂuorescently labeled (Cy5) SCO was used in complex for-
mation. The quantitative uptake assay helps to clarify the
relation between the amount of the internalized complexes
and their biological activity. Interestingly, despite the con-
gruency between the uptake data and the splice-correction
data in the absence of chloroquine, splice-correction was
signiﬁcantly increased in the presence of chloroquine
(Figure 4A). We have reported on similar patterns for
stearyl-TP10 (21). These data show that, although PF14
nanocomplexes display very efﬁcient splice-correction
activity, some of the complexes are entrapped in
endosomes and are released after endosomal rupture in
the presence of chloroquine. However, despite the
increased efﬁciency of PF14 in the presence of chloro-
quine, its basal activity levels are much higher than
those of stearyl-TP10 and LF2000. This proves that
PF14 is a very efﬁcient delivery vector; however, there is
space for improvement of its activity by further enhance-
ment of endosomal escape. To corroborate the role of
endocytosis in the uptake of PF14 nanocomplexes, trans-
fections were carried out at lowered temperature (4 C),
which is supposed to halt energy-dependent processes
like endocytosis. As expected, the transfection efﬁciency
of PF14 was markedly decreased at 4 C, indicating
the involvement of endocytic processes in the uptake
(Figure 4B). To visualize this process ﬂuoresceinyl-
labeled dextran, a marker for endocytosis (32), was used.
Co-localization between labeled dextran and Cy5-labeled
SCO in the cytoplasm strongly suggests a prominent role
of endocytosis in the uptake of PF14 nanocomplexes
(Figure 4C and Supplementary Figure S3).
Further characterization of the efﬁciency of PF14 was
done utilizing ﬂow-cytometry to assess the percentage
of cells being transfected. Importantly, PF14 was able
to transfect nearly 100% of the cell population
(Supplementary Figure S4), which explains the nearly
90% correction observed after 24h with RT–PCR
(Figure 2B). Upon testing PF14 over an increasing cell
density, it showed less sensitivity than LF2000 towards
variations in cell conﬂuency (Figure 5A). This is very im-
portant for in vitro screens that require different end-
points and for successful in vivo implementation where
the target is intact tissues. Comparing the cytotoxicity
of both vectors through the activity of mitochondrial
dehydrogenases showed that PF14 had no impact on the
cell viability and was signiﬁcantly less toxic than LF2000
even in serum-free conditions (Figure 5B).
Figure 8. Stability testing. Lactose-SD 3.33% formulations were stored either at RT (22 C) or in ovens of adjusted temperatures (40 and 60 C).
Samples were monitored for 8 weeks and tested at 0, 2, 4 and 8 weeks. Measurements were carried out in triplicates and differences were considered
signiﬁcant at *P<0.05 according to Student’s t-test.
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further by developing a suitable formulation for adminis-
tration. The formulation process is an indispensable step
for the development of any therapeutic product. It has
great effect on enhancing the efﬁciency and stability of
active pharmaceutical ingredients. Additionally, speciﬁc
formulations have to be tailored for different therapeutic
approaches. Among the different pharmaceutical forms
present, solid formulations remain the most widely used.
It is the form used in tablets, capsules, powders for inhal-
ation and even powders for injection. This is because they
are easy to handle and very stable upon storage and trans-
portation. Although CPPs have been extensively exploited
in recent years for the delivery of various therapeutics
(15), to our knowledge, formulation of CPPs into different
pharmaceutical forms has never been thoroughly studied.
Therefore, to expand the range of therapeutic applications
of CPP-based therapeutics, there is a need for studies
exploring the possibility of incorporating CPPs in differ-
ent pharmaceutical forms; especially the solid form. To
test the feasibility of formulating PF14-SCO complexes
into solid formulation, solid dispersion technique was
utilized. Although initially invented to increase the solu-
bility of poorly water-soluble drugs by dispersing them
over hydrophilic solid matrices (33), it is not used for
the same purpose in the present work. This is because
PF14-SCO complexes are already water-soluble.
However, the technique was adopted to enable us obtain
uniform distribution of the nanocomplexes over water-
soluble excipients by solvent evaporation. For solvent
evaporation (in this case water), we chose speed drying
under elevated temperature (55–60 C) and reduced pres-
sure. Despite being relatively stressful drying method, it is
more relevant to the widely used, cost-effective, heat-
based pharmaceutical drying techniques. As shown in
Figure 6, we found that that lactose-SD 3.33% was the
most optimal formulation, achieving splice-correction
activity similar to that of the freshly prepared complexes
in solution. Mannitol solid dispersions mediated lower
activity, while PEG formulations were the least active.
It was clear that different excipients and concentrations
thereof had a huge impact on the activity of the formula-
tion. This suggests that excipients affect the nano-
complexes in different ways. The nanocomplexes are
formed by non-covalent electrostatic interactions with
the ON. Therefore, different excipients varying in their
surface charge distribution could interfere with these inter-
actions affecting the physicochemical properties of the
nanocomplexes and eventually the biological activity.
However, an excipient concentration of 3.33% is shown
to be relatively superior in all the excipients tested, which
suggests that there is an optimal ratio between the concen-
tration of nanocomplexes in solution and the amount of
solubilized solid material. On the contrary, LF2000 almost
lost its entire activity upon application of this drying and
dispersion procedure (Figure 6). The success of PF14-SCO
complexes to withstand harsh drying and dispersion pro-
cedure at which the widely used commercial lipid-based
vector failed suggests that PF14-SCO nanocomplexes are
physicochemically more stable than the lipoplexes, yet
biologically more active. Additionally, we characterized
the effect of formulation on the kinetics of splice correc-
tion obtained by the best formulation (lactose-SD 3.33%).
We found that it demonstrated similar kinetic proﬁle to
the freshly prepared nanocomplexes (Supplementary
Figure S5).
In order to assess that the presence of intact nano-
complexes after the formulation procedure, DLS studies
were performed comparing the freshly prepared nano-
complexes with the solid formulations obtained after
drying at 50–60 C . We found that the particles size and
particle-size distribution is highly affected by the type of
excipient used (Figure 7 and Table 2). Lactose-SD 3.33%
formulation, which mediated the highest splice-correction
activity, also had DLS proﬁle most similar to the freshly
prepared nanocomplexes. This proves that the choice of
excipient for formulation of such nanocomplexes is an
extremely important step that affects both their physico-
chemical properties and biological activity. Yet, another
physicochemical property that could affect the biological
activity is the zeta potential. Particles of different surface
charge are expected to have distinct interactions with
the plasma membrane, which should affect the uptake
mechanism and efﬁciency of the delivery vector. We
expected that a cationic CPP-based nanocomplex should
possess net positive surface charge. Surprisingly however,
we found that all the nanocomplexes, either freshly
prepared or in solid formulation, with or without serum,
possessed a net negative charge. The efﬁciency of such
nanocomplexes can be explained in light of earlier
research on lipoplexes showing that cationic liposome
and plasmid DNA complexes are negatively charged
under optimal transfection conditions (34) and that this
holds in vivo as well (35). In further research studying the
uptake mechanisms of CPPs it will be interesting to eluci-
date how this net negative charge affects the interaction
with the plasma membrane and the biological activity.
Next, we subjected the best performing formulation,
lactose-SD 3.33%, to stressful stability testing conditions
at elevated temperatures for 2 months. Storage at high
temperatures increases the rate of degradation reactions
that could take years to occur (36). For this reason this
method is routinely used to assess the long-term stability
of formulations (27,28,37–39). Lactose-SD 3.33% formu-
lation demonstrated high stability over the tested time
period with no signiﬁcant loss in transfection efﬁciency
at most of the time points (Figure 8). The only signiﬁcant
decrease in activity was the 60 C 8-weeks time point,
where it was  70% of the initial activity. However, this
is a remarkably good stability proﬁle for a plain formula-
tion without any type of preservatives, coating or special
packaging. In addition, these results further corroborate
the high stability of PF14 nanocomplexes. In comparison
with solid formulation of lipoplexes, PF14 nanocomplexes
demonstrate very good activity and stability proﬁles.
Earlier reports showing that lipoplexes could be dried
over solid matrices mainly utilized the freeze-drying tech-
nique in the presence of lyoprotectant sugars like trehal-
ose, mannitol or sucrose (38–40). However, despite using
sufﬁcient levels of lyoprotectant sugars, signiﬁcant
damage was still evident when dilute lipoplex preparations
were subjected to freeze-drying (28). This damage occurs
5296 Nucleic Acids Research, 2011,Vol.39, No. 12during the freezing step, and sugars have a limited
capacity to protect against freezing-induced damage (28).
Furthermore, industrially, the freeze-drying (lyophiliza-
tion) process is known to be much more cumbersome
and costly than the conventional heat-based pharmaceut-
ical drying procedure. Additionally, it was shown that
the lyophilized lipoplexes suffered progressive loss in
transfecetion efﬁciency when subjected to stability
settings similar to what we have used in the present
study (27). The degradation was mainly due to the gener-
ation of reactive-oxygen species and was increased in the
presence of metal contaminants (27,37). Consequently,
chelators were used to enhance the stability proﬁle;
however, the effects of these additives on vector stability
during lyophilization are difﬁcult to predict (37). To our
knowledge, PF14istheﬁrst vectorreportedtoretainnearly
100% of its transfection efﬁciency utilizing a heat-based
drying and dispersion procedure. Furthermore, PF14
showed a very good stability proﬁle in the absence of add-
itional formulation requirements.
In conclusion, we have shown that the chemically
modiﬁed CPP, PF14, is able to efﬁciently deliver SCOs
to different cell-lines including a disease-relevant hard-
to-transfect cell-line, H2K. Furthermore, we have success-
fully been able to formulate PF14-SCO nanocomplexes
into solid formulation utilizing the solid dispersion tech-
nique using a convenient heat-based drying method. The
solid formulations demonstrated splice-correction activity
almost identical to the freshly prepared nanocomplexes;
however, this efﬁciency was sensitive to the type of excipi-
ent used and its concentration. The nanocomplexes
remained intact after formulation and the formulation
remained active even when subjected to stressful stability
conditions for 2 months. Importantly, being able to for-
mulate PF14 nanocomplexes into an active and stable
solid formulation is an important proof-of-principle
that CPP-based therapeutics could be incorporated in
solid pharmaceutical forms. This could signiﬁcantly
extend the horizon of therapeutic applications of CPPs.
Collectively, our results suggest that PF14 is a promising
translational approach for delivering SCOs in different
pharmaceutical forms and opens new opportunities to
develop more pharmaceutically relevant assays for CPPs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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